Rosalind Research Observatory

Cycle 6 · 2026-09-25

AI Biomedical Convergence Tracker — Cycle 6

Anthropic's named enzyme-system discovery strengthened the scientific-agent layer while an AbbVie-Iambic deal expanded the multi-pharma adoption pattern; no capture-event gate crossed.

Boundary: Independent public-source observatory. Not affiliated with OpenAI, Novo Nordisk, Rosalind Biodefense, GPT-Rosalind, Huawei, or any access program. No medical advice, biological protocols, laboratory guidance, access brokerage, or operational enablement is provided.
1Elevated
1Alert
1/7Chinese-primary
30Held for primary

Capture-event state

P1: not_crossed P2: not_crossed P3: not_crossed P4: partial

Source integrity

Immutable report source

Published from the Cowork Scout report with SHA-256 553ebf50565326fae2f240c606e24145f40cbf04914201246f85cfc2ffb201e4. The complete Markdown is also available as report.md.

Primary anchors

AI Biomedical Convergence Tracker — Cycle 6 Scan Report

Scan date: 2026-09-25 (Fri 12:00 UTC target; scheduled task fired 12:13 UTC) Window: 2026-09-22 → 2026-09-25 (Fri sweep after 2026-09-22 Tue Cycle 5; +3d cadence) Runner: Cowork Scout 🏹 Baseline read: ~/Codex/Claude_coworker_folder/AI Biomedical Convergence Tracker — Recurring Task.md — read in full, absorbed all six clusters, PROMPT_OBSERVED discipline header, held-for-primary MANDATORY LIST, four-part capture-event test, convergence tags, frame-contest hooks. Prior report read: Cycle 5 (2026-09-22) — 28 held items carried forward, Isomorphic silence-signal at Alert-tier held (four consecutive cycles), three baseline-patch proposals from Cycle 5 (Cluster 5 NATIONAL_CHAMPION_CONSOLIDATION substamp firming, Huawei-anchor counterparty roster expansion to Zhendong, zh sweep methodology re-baselining) still awaiting terminal Scout fold-in.

SCAN_RESULT_AND_PATCH_PROPOSAL

[CLUSTER 1 — FRONTIER AI SCIENTIFIC MOVES] — IN-WINDOW ALERT (Anthropic materialization of scientific-agent layer with named discovery output)

Signal: On 2026-09-23, Anthropic published a primary announcement that Claude — operating as approximately 950 parallel agents for ~21 hours consuming ~210M tokens — analyzed a massive DNA sequence database and identified a novel enzyme system named ART (Array-Associated Reverse Transcriptases): reverse-transcriptase enzymes with CRISPR-like repeat patterns found in bacteriophages. The system comprises three components (a reverse transcriptase, an associated partner gene, and evenly-spaced DNA repeats expressed as distinct short RNAs). Wet-lab characterization ran at Anthropic's Bay Area BSL-1/BSL-2 facility; all laboratory work was performed by human scientists, not by MHS-driven robots. The work used Claude Science and Claude Code tools. Feng Zhang (MIT / Broad Institute; CRISPR pioneer) reviewed the pre-print and is quoted: "This is an exciting example of how AI agents can contribute to biological discovery." Therapeutic implications are described as "not yet determined; the system's primary function remains under investigation." This is the first Anthropic primary that names a specific novel biological discovery output attributable to the Claude Science + Claude Code scientific-agent stack.

Primary URL:

Confirmation tier: OFFICIAL (Anthropic primary announcement page with named collaborator Feng Zhang direct-quote attestation on pre-print review; a pre-print DOI/URL is referenced in the announcement but the pre-print venue itself is a distinct primary Scout has NOT byte-checked this cycle — HELD for primary next cycle)

Type: frontier-agent-release + scientific-workbench (Claude Science + Claude Code productization yielding a named discovery output) + capability-shift (agent-orchestration at 950-agent parallel scale × 21h × 210M tokens is a discrete new capability primitive) + academic-frontier (novel enzyme-system pre-print with Feng Zhang review)

Consequence class: capability-shift (Anthropic materializes the scientific-agent layer with a named discovery output at published-scale-of-orchestration; this is a Cluster 1 primitive-firming beyond prior workbench + tools release) + infrastructure-availability (the 950-agent × 21-hour orchestration pattern is a substantive primitive that other frontier labs will benchmark)

Contradicts_baseline: false — advances Cluster 1 baseline SCIENTIFIC_AGENT_LAYER_STRENGTHENING with concrete named discovery output. Does NOT contradict Cluster 4 baseline PRIMITIVE_SHIPPING (MHS) — announcement is explicit that "all laboratory work was performed by human scientists," so MHS integration for the wet-lab characterization step is NOT confirmed by this signal.

Contradiction_note: n/a. But three frame-contest disciplines apply:

  1. Hook #7 (AI-designed vs AI-assisted): ART discovery methodology is agent-driven BIOINFORMATICS (sequence-database analysis) + human-run WET-LAB characterization. This is NOT an AI-designed drug event and MUST NOT be reported as one. The discovery is of a naturally-occurring enzyme system in bacteriophages, not a molecule designed by AI. Preserve the distinction: AI-driven discovery of natural biology is a Cluster 1 capability signal; AI-designed therapeutic molecule is a Cluster 2 event. Do NOT fuse.
  2. Hook #5 ("Closed-loop lab is here"): The wet-lab step in this run was HUMAN-SCIENTIST-RUN, not agent-driven robotic operation. MHS remains research preview. The ART discovery signal DOES NOT upgrade Cluster 4 from PRIMITIVE_SHIPPING to PRODUCTION_DEPLOYMENT or LOOP_CLOSURE_MEASURABLE_ADVANTAGE. Cluster 4 status stamp UNCHANGED. Preserve the wet-lab-detection-method-UNKNOWN discipline per PROMPT_OBSERVED (5).
  3. Hook #3 ("Anthropic is the leader in AI-pharma"): This signal materially firms Anthropic's Cluster 1 primitive-shipping position with a specific named discovery output — but leadership on Cluster 2 clinical, Cluster 3 deal-value, and Cluster 4 wet-lab agent-driven physics remains partitioned across different actors. Preserve stack-sequencing discipline; do NOT collapse to single-vendor leadership attribution.

Convergence_tag: none (nearest fit would be closed_loop_lab Cluster 1 + Cluster 4, but the wet-lab step is human-scientist-run per Anthropic primary, so the closed-loop convergence tag is NOT earned by this signal — the tag is reserved for agent-driven wet-lab closed loop). Note weak ancillary tie to open_source_challenges_incumbent (Cluster 1 + Cluster 6) via academic-frontier vector: Feng Zhang / Broad Institute review of a private-lab pre-print is an academic-frontier crossover signal in the direction of frontier-lab-to-academic-lab collaboration.

Why it matters: (a) Cluster 1: First Anthropic primary that names a specific novel biological discovery output attributable to the Claude Science + Claude Code stack — moves from "tools + workbench released" (Cluster 1 baseline anchor) to "tools + workbench yielding named biological discovery with third-party CRISPR-pioneer endorsement." Baseline-patch candidate for terminal Scout: consider firming SCIENTIFIC_AGENT_LAYER_STRENGTHENING substamp toward SCIENTIFIC_AGENT_LAYER_DISCOVERY_OUTPUT_DEMONSTRATED (or equivalent). The 950-agent × 21-hour × 210M-token orchestration parameters are additionally a discrete capability primitive that will now benchmark other frontier labs' comparable pipelines. (b) Cluster 4 (clean-side stake): Signal explicitly does NOT firm Cluster 4 — human-scientist-run wet lab is NOT agent-driven closed-loop lab. Cluster 4 status UNCHANGED. But the pattern hints at a bidirectional-stack-closing acceleration: if Anthropic ran wet-lab validation via human scientists in the announcement window, and separately MHS remains research preview, then the NEXT structural transition to watch is whether Anthropic's own Bay Area wet lab integrates MHS-driven robotic operation in a subsequent primary. That transition would earn the closed_loop_lab convergence tag; nothing this cycle earns it. (c) Capture-event Part 1 test: NOT crossed. Anthropic 09-23 is agent-driven bioinformatics + human-run wet-lab characterization — that is not the four-part-test Part 1 shape ("closed-loop wet-lab primitive shipping at production scale"). Preserve four-part-test evidence discipline: no upgrade without agent-driven wet-lab action + real molecular hit. (d) Frame-contest hook #6 firming: the 950-agent parallel-orchestration scale is a specific capability primitive that does NOT translate to a Cluster 4 wet-lab primitive by same-shape reasoning. Preserve subtask-boundary discipline. (e) Cross-tie signal on academic-frontier vector: Feng Zhang (MIT / Broad) review of an Anthropic-private-lab pre-print is a structural bridge between the frontier-lab private-substrate and the academic-frontier open-substrate — small signal but crystallizes a pattern where Cluster 1 output loops back through Cluster 6 academic review before publication.

Urgency: Alert (first named biological-discovery output from Anthropic's Cluster 1 substrate stack; discrete new capability primitive; capture-event-adjacent even though four-part-test discipline holds no part crossed)

Cross-tie: Cluster 6 (academic-frontier vector via Feng Zhang / Broad Institute pre-print review); model-intelligence-tracker (950-agent × 21h × 210M-token orchestration is a scale-of-agent-run capability primitive at the model-orchestration layer, distinct from single-agent capability benchmarks); frame-contest-tracker (hook #7 firming — "AI-assisted natural-biology-discovery" IS explicitly distinguished from "AI-designed therapeutic molecule"; hook #5 firming — human-run wet lab IS explicitly distinguished from agent-driven closed-loop lab; hook #3 clean-side stake — leadership partitioning across clusters preserved); agent-commerce-tracker (indirect — the 950-agent orchestration pattern is at agent-scale commerce economics distinct from single-user Claude usage)

[CLUSTER 3 — BIG-PHARMA AI ADOPTION] — IN-WINDOW ELEVATED (late-catch from Cycle 5 window boundary)

Signal: On 2026-09-21, AbbVie (NYSE: ABBV) and Iambic Therapeutics announced an AI-driven drug-discovery collaboration in immunology, neuroscience, and oncology using Iambic's "molecular superintelligence platform" powered by Enchant v3 (multimodal transformer trained on 6,000+ molecular properties) and NeuralPLexer. Deal financials: upfront (undisclosed) + success-based milestones (undisclosed) + tiered royalties on net sales (tiers undisclosed). Total deal value not disclosed. Number of targets not specified. Iambic's second big-pharma customer in 2026 (following Bayer, June 2026 baseline; and existing Roche 2026 collaboration per prior cycles). Late-catch: this landed 2026-09-21, within Cycle 5's window boundary (2026-09-18 → 2026-09-22 Tue close); Cycle 5 did not surface it. Cycle 6 flags for baseline-ledger completeness.

Primary URL:

Confirmation tier: OFFICIAL (PR Newswire distribution of joint AbbVie + Iambic press release; secondary PharmExec pickup with named AbbVie EVP quote)

Type: pharma-deal + enterprise-deployment (Iambic platform integration into AbbVie R&D)

Consequence class: deal-market-repricing (adds a new named pharma-Iambic pair to Cluster 3 platform-deal-market roster — extends the Iambic customer stack from Bayer + Roche to Bayer + Roche + AbbVie in 15 months) — but NOT displacing the $2.75B Insilico+Lilly (2026-03) benchmark and NOT crossing $3B new-anchor threshold, because financials are undisclosed

Contradicts_baseline: false — advances Cluster 3 platform-deal-market roster without contradiction. Does NOT contradict Frame-contest hook #7 discipline: the deal press describes Enchant v3 as "optimizing candidate properties simultaneously" and NeuralPLexer as complex-prediction, i.e. AI-assisted screening/optimization of candidates, NOT AI-driven target/lead materially-driven-by-AI-method. Classification per hook #7 discipline: AI-assisted collaboration, NOT AI-designed drug program.

Contradiction_note: n/a. Two frame-contest disciplines apply:

  1. Hook #7 (AI-designed vs AI-assisted): "molecular superintelligence platform" is marketing language; the described mechanism is property optimization + parallel hypothesis testing at scale — AI-assisted, not AI-designed. Do NOT promote to AI-designed drug program without primary text confirming molecule structure / target selection / lead optimization materially driven by AI method.
  2. Hook #6 (Subtask-boundary preservation): Iambic's Bayer + Roche + AbbVie pattern is a three-customer scaling of Cluster 3 adopter shape; do NOT project matching deal-value scale across the three customers when only Bayer (June 2026 baseline, dollar figure not previously baseline-confirmed) has any prior baseline attribution and AbbVie is undisclosed-value.

Convergence_tag: none (Cluster 3 solo; weak indirect Cluster 1 tie via Iambic's Enchant + NeuralPLexer as scientific-workbench substrate, but the deal is a pharma-customer transaction, not a substrate release)

Why it matters: (a) Cluster 3: New named pharma-Iambic pair extends Iambic customer stack; the three-customer Iambic pattern (Bayer + Roche + AbbVie) is a specialist-AI-biotech-with-multi-big-pharma-customer shape parallel to the multi-vendor Novo Nordisk pattern surfaced in Cycle 4 (Novo three-vendor OpenAI + AWS + Anthropic). Baseline-ledger completeness patch: add AbbVie-Iambic to Cluster 3 deal ledger between "Bayer + Iambic Therapeutics" and "Owkin + Boehringer Ingelheim" as counterparty-shape 2026-09-21. (b) Capture-event Part 3 test: NOT crossed. AbbVie-Iambic is undisclosed-value; does not meet or exceed $2.75B benchmark; does not deprecate via cancellation cluster. Preserve Part 3 status_stamp: not_crossed. (c) Silence-signal noted for Cycle 5: Cycle 5 report did not surface this in-window signal. Not a discipline failure — the deal landed 2026-09-21 within a same-week Cycle 5 sweep with Chinese-primary as the material productivity axis, and PR Newswire pharma-deal coverage was the miss. Cycle 6 methodology adjustment: extend the standing en-language sweep path set to always include prnewswire.com filtered by "AI drug discovery" during each cycle, given the pharma-deal PR-cycle vector.

Urgency: Elevated (new Cluster 3 counterparty pair; undisclosed financials keep it from Alert tier; Iambic three-customer shape firming warrants baseline-ledger completion)

Cross-tie: frame-contest-tracker (hook #7 discipline — Enchant/NeuralPLexer is AI-assisted, not AI-designed); model-intelligence-tracker (indirect — Iambic Enchant v3 multimodal transformer as vertical-specialist substrate parallel to GPT-Rosalind / Claude Science on general-purpose vertical substrate; different physics, note but do not fuse)

[CLUSTER 5 — SOVEREIGN AI-PHARMA] — IN-WINDOW ROUTINE (adjacent, non-pharma; roster-shape discipline)

Signal: On 2026-09-23 at a "Wisdom·Symbiosis" (智汇) smart-healthcare seminar in Chengdu, Maccura Biotech (迈克生物, SZ 300463) and Huawei jointly launched a "Zhihui Lab AI Integrated Machine" (「智汇」实验室AI一体机) — a unified compute + AI platform embedding Huawei's AI infrastructure into Maccura's in-vitro-diagnostics (IVD) workflows. Event framed as shifting labs from "passive response" to "active intelligent governance." Designated a "Maccura & Huawei Xinxing AI High-Quality Park Network Demonstration Point"; WiFi 7 deployment showcased across facilities. No dollar figures, delivery milestones, or wet-lab-automation claims disclosed. Government leadership attendance referenced but no explicit state-ownership language.

Primary URL:

Confirmation tier: OFFICIAL (10jqka.com.cn stock news aggregator with named event + parties + Maccura SZ 300463 corporate attribution; direct Huawei corporate primary landing page for the launch not located this cycle — HELD for primary next cycle)

Type: enterprise-deployment (Huawei compute stack embedded in Maccura IVD lab platform) + scientific-workbench (adjacent — IVD lab AI integrated machine, not drug-discovery workbench)

Consequence class: infrastructure-availability (Huawei compute stack extends into IVD lab vertical) — but adjacent to Cluster 5 AI-pharma joint-lab roster, NOT a roster addition

Contradicts_baseline: false — but is an adjacency signal, NOT a Huawei-anchor pharma joint-lab expansion. Maccura is an IVD (in-vitro diagnostics) company, structurally distinct from the drug-discovery pharma counterparties in the Cluster 5 Huawei-anchor pharma roster (Guangzhou Pharmaceutical Holdings + StoneWise + Yunnan Baiyao + Zhendong Pharmaceutical, per Cycle 5 baseline-patch proposal awaiting terminal Scout fold-in). Do NOT expand the Huawei-anchor pharma roster to include Maccura. Preserve subtask-boundary discipline per hook #6.

Contradiction_note: n/a. Three frame-contest disciplines apply:

  1. Hook #6 (Same-shape ≠ same-rule): Maccura + Huawei "Zhihui Lab AI Integrated Machine" is same-shape (Huawei-anchor + AI-lab-launch) as the Guangyao + Huawei / Zhendong + Huawei joint innovation laboratory launches at Huawei Connect 2026 (Cycle 5 signal), but same-shape ≠ same-rule: Maccura's core business is IVD diagnostic instrumentation, not AI drug discovery. Do NOT fuse to the pharma-joint-lab pattern. Distinct physics.
  2. Hook #2 (AI drug era has arrived): Maccura + Huawei IVD lab AI launch is NOT an AI-designed-drug event and NOT an AI-pharma joint-lab event. Preserve direction of the arrow.
  3. Hook #8 (Sovereign fund investment proves government belief): Government leadership attendance at Chengdu event is state-industrial-policy-layer signaling on IVD vertical; NOT a sovereign-fund-capital-allocation signal on AI-pharma vertical. Preserve the distinction — capture-event Part 4 test remains partial.

Convergence_tag: none (Cluster 5 solo, adjacent scope). Very weak indirect tie to sovereign_ai_pharma (Cluster 1 + Cluster 5) via Huawei-ecosystem-continued-expansion, but at IVD-adjacent rather than pharma-vertical scope.

Why it matters: (a) Cluster 5: Huawei ecosystem expands into IVD lab vertical via Maccura Zhihui Lab AI Integrated Machine — same-shape as the Guangyao + Zhendong Huawei-anchor pharma joint-lab launches at Huawei Connect 2026 (Cycle 5 anchor), but at IVD-adjacent scope. Signals that Huawei's vertical-AI-lab pattern is a repeated formula Huawei is deploying across multiple healthcare-adjacent verticals (pharma joint-lab + IVD integrated machine + potential future adjacent verticals). This is a Huawei-substrate-scaling signal, NOT a Cluster 5 NATIONAL_CHAMPION_CONSOLIDATION firming beyond Cycle 5. (b) Roster-shape discipline stake: Maccura is NOT added to the Cluster 5 Huawei-anchor pharma roster. This is a clean-side hook #6 subtask-boundary stake — preserving the drug-discovery-pharma vs IVD-diagnostics distinction is load-bearing for the tracker's frame integrity. (c) Capture-event Part 4 test: UNCHANGED (partial). Maccura-Huawei is state-industrial-policy signaling on IVD vertical, not sovereign-fund-capital or regulator-naming-AI-designed-drugs. (d) Chinese-primary continuity: the widened zh sweep methodology (Cycle 5 baseline-patch proposal awaiting terminal Scout fold-in) continues to yield productive Chinese-primary output — this cycle surfaced Maccura + Huawei via the 10jqka.com.cn path.

Urgency: Routine (adjacent-scope signal; no roster expansion; no capture-event part crossed; Huawei-substrate-scaling context only)

Cross-tie: sovereign-events-scout (Huawei-ecosystem widening across healthcare-adjacent verticals — vertical-lab-AI as repeated formula); frame-contest-tracker (hook #6 clean-side stake — IVD vs pharma drug-discovery subtask boundary preserved; hook #2 clean-side stake — IVD lab AI is not "AI drug era arrived"; hook #8 clean-side stake — state-industrial-policy is not sovereign-fund-capital); agent-commerce-tracker (indirect — Huawei-substrate-as-repeated-formula scaling pattern is at commerce-loop economics; note but do not fuse)

CLUSTERS WITH NO NEW SIGNAL ABOVE BASELINE

MANDATORY CLOSE

Total unique primary URLs opened this scan: 7 primaries + 6 secondaries.

Held-for-primary list (carried forward, per MANDATORY LIST discipline — nothing silently dropped):

Carrying forward unchanged (per MANDATORY LIST):

Resolved this cycle (removed from held; primary confirmed): none this cycle.

Added to held-for-primary this cycle:

Chinese-primary share: 1 / 7 = 14.3%. Below the 20% threshold. NOTE: this is NOT a re-triggering of the "third-consecutive-sub-20%-Chinese-primary" flag (which was answered and cleared in Cycle 5 via widened zh sweep methodology yielding 55.6% share). Cycle 6 is a single-cycle sub-20% event driven by the material Cluster 1 in-window English-primary anchor (Anthropic 2026-09-23 ART announcement) which correctly dominates the primary-URL count this cycle. The widened zh sweep methodology (10jqka + Tencent + ifeng + gpc.com.cn + 163 + sina + WeChat public-account paths) was applied this cycle and yielded one productive Chinese-primary (Maccura + Huawei via 10jqka path). Do NOT re-flag; single-cycle sub-20% is expected and healthy when English-primary in-window signal is materially productive. Re-flag only if Chinese-primary share stays sub-20% for three consecutive cycles.

Language coverage this scan: en (dominant for Anthropic ART + AbbVie-Iambic + Isomorphic/Insilico newsroom sweeps + Cluster 4/Cluster 6 open-source searches); zh (10jqka Maccura-Huawei path — materially productive at single-signal scale). ja / de / ko / fr: absent this window (not a failure mode this cycle — the two Cluster 1 + Cluster 3 in-window signals are English-primary, and the null clusters do not require ja/de/ko/fr coverage for signal-discovery in this window).

Canonical state mutated: false (Cowork produces patch proposal only; terminal Scout writes baseline + .tracker_state/ai_biomedical_convergence_state.json — per gotcha #6, sandbox mount ≠ live ~/Codex filesystem for baseline JSON writes)

Cluster state at close:

Capture-event four-part test at close:

No auto-escalate. No publish-lane propagation. Zero of the four parts crossed. Report + operator awareness only, per baseline termination-conditions discipline.

Cross-tracker routing:

Silence-clusters named (explicit-silence IS signal):

Next recommended scan: Tue 2026-09-29 12:00 UTC — default 2×/week cadence maintained. Do NOT escalate to daily. Zero capture-event parts crossed. Isomorphic silence-signal escalated to FIFTH consecutive cycle Alert-tier held — Cycle 7 recommendation: structural review of "Isomorphic-Davos-commit-slip" hypothesis and prep operator-awareness message. Escalation conditions unchanged: (a) Phase 3 positive primary endpoint, (b) FDA/EMA/NMPA/PMDA AI-designed-drug approval, (c) MHS production-customer named deployment, (d) $3B+ new-window platform deal / sovereign fund naming AI-pharma / regulator naming AI-designed drugs as a distinct approval class, (e) Anthropic Bay Area wet-lab MHS integration for follow-on ART-shape discovery run.

Recency-stamp compliance: pass. In-window Anthropic ART discovery 2026-09-23 primary; Anthropic Ebola features 2026-09-22 primary; AbbVie + Iambic 2026-09-21 primary (late-catch, correctly labeled); Maccura + Huawei 2026-09-23 event / 2026-09-24 aggregator primary. Insilico + SK Biopharm 2026-06-29 primary explicitly labeled as pre-window BIO 2026 baseline-ledger gap. Anthropic biology-lab Reuters/CNBC 2026-09-18 explicitly labeled as pre-window Cycle 4/5 boundary context. No quoted text without byte-match. No out-of-window dates unmarked. Isomorphic 2026-07-16 bioresilience post explicitly labeled as most-recent primary preceding five-cycle silence.

Convergence-signature gate: clears internal stamp for baseline patch consideration by terminal Scout. Specific baseline patches proposed for Cycle 6:

  1. Cluster 1 substamp candidate: consider firming SCIENTIFIC_AGENT_LAYER_STRENGTHENING toward SCIENTIFIC_AGENT_LAYER_DISCOVERY_OUTPUT_DEMONSTRATED (or equivalent) based on Anthropic 2026-09-23 ART enzyme-system discovery — first named biological-discovery output from the Claude Science + Claude Code stack with 950-agent × 21-hour × 210M-token orchestration parameters and third-party CRISPR-pioneer (Feng Zhang) pre-print endorsement.
  2. Cluster 1 baseline entry candidate: add Anthropic 2026-09-23 ART discovery to Cluster 1 baseline as anchor primary, with explicit hook #7 classification (AI-driven natural-biology-discovery, NOT AI-designed drug) and explicit hook #5 classification (human-scientist-run wet lab, NOT agent-driven closed-loop). Attach convergence tag none and note weak Cluster 6 academic-frontier crossover via Feng Zhang review.
  3. Cluster 3 deal-ledger completeness patch: add Insilico + SK Biopharmaceuticals $2.5B neuroimmune-disorder collaboration (2026-06-29 primary: insilico.com/news/tt2t6rbzr1-insilico-medicine-caps-monumental-week-a) to Cluster 3 baseline deal ledger between "Insilico + Eli Lilly $2.75B (2026-03)" and "Isomorphic + Lilly (2024-01-07)" as counterparty-shape 2026-06 BIO conference-vintage anchor.
  4. Cluster 3 deal-ledger add: AbbVie + Iambic Therapeutics (2026-09-21 primary: prnewswire.com AbbVie + Iambic 302883724) as new counterparty pair in Cluster 3 baseline deal ledger; undisclosed financials; classify AI-assisted (Enchant v3 + NeuralPLexer optimizes candidate properties; NOT AI-driven target/lead) per hook #7 discipline. Note Iambic three-customer pattern (Bayer + Roche + AbbVie) as multi-big-pharma-customer specialist-AI-biotech shape.
  5. Cluster 5 no-patch: Maccura + Huawei IVD lab AI Integrated Machine (2026-09-23 event / 2026-09-24 primary) is IVD-adjacent, NOT a Cluster 5 pharma-roster expansion. Preserve hook #6 subtask-boundary. Note in Cluster 5 baseline as Huawei-substrate-scaling context signal.

Cowork does not mutate baseline (gotcha #6).

Report path: ~/Codex/Claude_coworker_folder/trackers/ai-biomedical-convergence/reports/ai-biomedical-convergence-tracker_2026-09-25.md

Runner: Cowork Scout 🏹 | Cycle: 6 (Fri after 2026-09-22 Cycle 5)